Great to see RHC reclaiming its place at the heart of modern cardiology. A full room, active discussions, and genuine scientific curiosity—exactly what #CardioAlex26 is all about.

Reflecting on SAPH2026, Day 2 of the Conference continued the scientific momentum with high-level plenary sessions and multidisciplinary discussions that deepened the academic dialogue in pulmonary vascular medicine. The program featured comprehensive presentations addressing evolving standards of care, emerging therapeutic strategies, complex case management, and key research updates in pulmonary hypertension. These sessions enabled meaningful exchange among experts and reinforced alignment with contemporary international guidelines. Distinguished national and international faculty contributed to focused discussions highlighting advances in clinical pathways, targeted therapies, and practical approaches to optimizing patient outcomes. The breadth and depth of the day’s program reflected the strength of the scientific agenda and the collective commitment to advancing specialized care. Day 2 concluded with continued engagement across disciplines, sustaining the conference’s scientific rigor and professional collaboration. #SAPH2026

#ESC75Years #CVHealthForAll #LetsRise2025 #ESCCongress @ACVCPresident @PabloJ @drdargaray @drmilicaa @RThachilMD @Hragy @HannahSchaubro1 @rafavidalperez @veramasloo

#PH #ESCCongress

Pulmonary hypertension @milica_yb @EuroRespSoc #ESCCongress2025

Gp 1 PH with high HFpEF probability have less clinical improvement with traditional PH therapy, compared to gp 1 PH + low HFpEF prob. Do we need more intensive PH therapy, sotatercept or HFpEF therapies for these pts? Many unknowns that need RCTs. publications.ersnet.org/cont…

Reviving the “lost” art of RHC (Right Heart Cath) our course launches , the first presentation of many to come.. We are happy to collaborate with all those whose areas of practice need revival of RHC.. #CardioAlex2025

RT @Estrella7Stella: This man is documenting history through his art ♥️

The first participant has been dosed in Foresee's Phase 2 trial testing the experimental oral therapy mirivadelgat in people with PH-ILD. buff.ly/PkU1Yy2

Sometimes, it's PH 🦓 Yoko from Japan has been living with pulmonary arterial hypertension (PAH) for over 20 years. Despite the challenges, she continues to move forward with the help of oxygen, epoprostenol, and an unwavering sense of hope. ⤵️

Pulmonary hypertension (PH) causes breathlessness and a fast heartbeat. It is often hard to diagnose because many people with PH have other health conditions. Help us raise awareness and support those living with PH. 💡 Learn more: europeanlung.org/en/informat…

Arrivé en Égypte avec de fiers compagnons de vol : des Rafale égyptiens, symbole fort de notre coopération stratégique.

It's all in prehospital phase - extraordinary talk by Carolina Malta Hansen #ACVC2025 @escardio @PabloJ @Ana_Viana_T @randreariba_rut @joyland2704 @ACVCPresident

Proud to present the hemodynamic effects of lactate infusion in #cardiogenicshock at @escardio #ACVC2025: Increased CO due to increased SV, enhanced ventriculo-arterial coupling and improved mitochondrial function 🫀 Full article published in @Crit_Care doi.org/10.1186/s13054-025-0…

Which patients with atrial fibrillation are likely to recover LVEF? @OtiliaTica1 at #ACVC2025

Setting up #ACVCmotions with #acvc2025 young investigators awardees @escardio #cvAcute #ACVC_ESC

Go to Level -1 - first session of moderated e-posters has just started #ACVC2025 @franciscojlk @CVandenbriele @rafavidalperez @PabloJ @ACVCPresident @escardio @HannahSchaubro1

Packed #ACVC2025 ! Run to the welcome address level 0 at the exhibition area!!! 🤓 @drdargaray @drmilicaa @ACVCPresident @escardio @DrMarthaGulati @HannahSchaubro1 @DrMarthaGulati @FH_Verbrugge @rafavidalperez